Stock Events

Stock Events

Leap Therapeutics 

$2.05
135
+$1.61+368.57% Wednesday 21:00
-$0.50-24.39%Thursday 00:59Pre-market

Statistics

Day High
2.54
Day Low
0.585
52W High
3.7
52W Low
0.2223
Volume
753,303,347
Avg. Volume
22,976,975
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

23MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
-0.52
-0.37
-0.22
-0.07
Expected EPS
-0.0664
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-93.88MNet Income

Analyst Ratings

$4.90Average Price Target
The highest estimate is 4.90.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap128.81B
Bristol Myers Squibb competes in the oncology space with a broad portfolio of cancer treatments, overlapping with Leap Therapeutics' focus on cancer immunotherapies.
Merck
MRK
Mkt Cap362.35B
Merck is a leading competitor in the oncology market, particularly with its blockbuster cancer drug Keytruda, which competes directly with cancer therapies developed by Leap Therapeutics.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its Genentech subsidiary, competes in the cancer treatment space, including immunotherapies that directly compete with Leap Therapeutics' pipeline.
Astrazeneca
AZN
Mkt Cap257.57B
AstraZeneca has a strong presence in the oncology sector, including immunotherapy treatments that rival Leap Therapeutics' cancer therapy developments.
Pfizer
PFE
Mkt Cap157.65B
Pfizer has a diverse oncology portfolio that includes immunotherapies and targeted cancer treatments, competing with Leap Therapeutics' focus areas.
Gilead Sciences
GILD
Mkt Cap186.13B
Gilead Sciences, through its Kite Pharma acquisition, competes in the cancer immunotherapy space, directly challenging Leap Therapeutics' therapeutic approaches.
AMGEN
AMGN
Mkt Cap208.49B
Amgen has a growing oncology and hematology portfolio that includes treatments which could compete with Leap Therapeutics' cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.8B
Regeneron Pharmaceuticals is involved in developing a range of cancer treatments, including immunotherapies that could compete with Leap Therapeutics' products.
Novartis
NVS
Mkt Cap266.8B
Novartis has a strong focus on oncology, with a portfolio that includes cancer immunotherapies and targeted treatments that rival Leap Therapeutics' developments.
Johnson & Johnson
JNJ
Mkt Cap650.65B
Johnson & Johnson, through its Janssen subsidiary, develops a variety of oncology treatments, including immunotherapies that could compete with Leap Therapeutics' pipeline.

About

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Show more...
CEO
Mr. Douglas E. Onsi J.D.
Employees
52
Country
Israel

Listings

STU
DE
5MC.STU
MU
DE
5MC1.MU
STU
DE
5MC1.STU
MU
DE
5MC.MU

0 Comments

Share your thoughts

FAQ

What is Leap Therapeutics stock price today?▼
The current price of LPTX is $2.05 USD — it has increased by +368.57% in the past 24 hours. Watch Leap Therapeutics stock price performance more closely on the chart.
What is Leap Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Leap Therapeutics stocks are traded under the ticker LPTX.
Is Leap Therapeutics stock price growing?▼
LPTX stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Leap Therapeutics has showed a +485.71% increase.
What is Leap Therapeutics revenue for the last year?▼
Leap Therapeutics revenue for the last year amounts to 0 USD.
What is Leap Therapeutics net income for the last year?▼
LPTX net income for the last year is -93.88M USD.
How many employees does Leap Therapeutics have?▼
As of September 27, 2026, the company has 52 employees.
In which sector is Leap Therapeutics located?▼
Leap Therapeutics operates in the Health & Wellness sector.
When did Leap Therapeutics complete a stock split?▼
The last stock split for Leap Therapeutics was on June 21, 2023 with a ratio of 1:10.
Where is Leap Therapeutics headquartered?▼
Leap Therapeutics is headquartered in Cambridge, Israel.